Open AccessBone morphogenetic protein‐10 (BMP‐10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer
Author(s) -
Ye Lin,
Bokobza Sivan,
Li Jin,
Moazzam Muhammad,
Chen Jinfeng,
Mansel Robert E.,
Jiang Wen G.
Publication year - 2010
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01648.x
Subject(s) - breast cancer , bone morphogenetic protein , immunohistochemistry , metastasis , cancer , bone morphogenetic protein 2 , medicine , cancer research , ca 15 3 , cancer cell , bone morphogenetic protein 7 , oncology , pathology , ca15 3 , biology , in vitro , gene , biochemistry
Our recent study showed that a novel member of bone morphogenetic protein (BMP) family, BMP‐10, was decreased in prostate cancer. In the present study, we investigated the implication of BMP‐10 in breast cancer, particularly the relation of its expression with clinical aspects. The expression of BMP‐10 was examined in a cohort of human breast cancer specimens (normal, n = 23; cancer, n = 97), using both quantitative real‐time PCR and immunohistochemical staining. The full‐length human BMP‐10 was cloned into a mammalian expression plasmid vector and then transfected into breast cancer cells. The effect on growth, cell matrix adhesion, motility, and invasion of MDA‐MB‐231 cells by BMP‐10 was then investigated using in vitro growth assays. Immunohistochemical staining and quantitative real‐time PCR revealed a decreased expression of BMP‐10 in breast cancer. Further analysis of BMP‐10 transcript level against the clinical aspect demonstrated that the decreased BMP‐10 expression correlated with disease progression, bone metastasis, and poor prognosis. The disease‐free survival of the patients with a higher level of BMP‐10 was 132.8 (95% CI, 122.0–143.5) months, significantly longer compared to 93.7 (95% CI, 60.3–127.2) months for patients with a lower level of BMP‐10 expression ( P = 0.043). The overexpression of BMP‐10 has broad inhibitory effects on the in vitro growth, invasion, and motility of breast cancer cells. Taken together, BMP‐10 can inhibit the cell growth of breast cancer cells, and decreased BMP‐10 expression correlates to poor prognosis and disease progression, particularly the lymphatic and bone metastasis. Bone morphogenetic protein‐10 (BMP‐10) may function as a tumor suppressor in breast cancer. ( Cancer Sci 2010)